TY - JOUR
T1 - Smarca4 Inactivation Promotes LineageSpecific Transformation and Early Metastatic Features in the Lung
AU - Concepcion, Carla P.
AU - Ma, Sai
AU - Lafave, Lindsay M.
AU - Bhutkar, Arjun
AU - Liu, Manyuan
AU - Deangelo, Lydia P.
AU - Kim, Jonathan Y.
AU - Priore, Isabella Del
AU - Schoenfeld, Adam J.
AU - Miller, Manon
AU - Kartha, Vinay K.
AU - Westcott, Peter M.K.
AU - Sánchez-Rivera, Francisco J.
AU - Meli, Kevin
AU - Gupta, Manav
AU - Bronson, Roderick T.
AU - Riely, Gregory J.
AU - Rekhtman, Natasha
AU - Rudin, Charles M.
AU - Kim, Carla F.
AU - Regev, Aviv
AU - Buenrostro, Jason D.
AU - Jacks, Tyler
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - SMARCA4/BRG1 encodes for one of two mutually exclusive ATPases present in mammalian SWI/SNF chromatin remodeling complexes and is frequently mutated in human lung adenocarcinoma. However, the functional consequences of SMARCA4 mutation on tumor initiation, progression, and chromatin regulation in lung cancer remain poorly understood. Here, we demonstrate that loss of Smarca4 sensitizes club cell secretory protein–positive cells within the lung in a cell type–dependent fashion to malignant transformation and tumor progression, resulting in highly advanced dedifferentiated tumors and increased metastatic incidence. Consistent with these phenotypes, Smarca4-deficient primary tumors lack lung lineage transcription factor activities and resemble a metastatic cell state. Mechanistically, we show that Smarca4 loss impairs the function of all three classes of SWI/SNF complexes, resulting in decreased chromatin accessibility at lung lineage motifs and ultimately accelerating tumor progression. Thus, we propose that the SWI/SNF complex via Smarca4 acts as a gatekeeper for lineage-specific cellular transformation and metastasis during lung cancer evolution. SIGNIFICANCE: We demonstrate cell-type specificity in the tumor-suppressive functions of SMARCA4 in the lung, pointing toward a critical role of the cell-of-origin in driving SWI/SNF-mutant lung adenocarcinoma. We further show the direct effects of SMARCA4 loss on SWI/SNF function and chromatin regulation that cause aggressive malignancy during lung cancer evolution.
AB - SMARCA4/BRG1 encodes for one of two mutually exclusive ATPases present in mammalian SWI/SNF chromatin remodeling complexes and is frequently mutated in human lung adenocarcinoma. However, the functional consequences of SMARCA4 mutation on tumor initiation, progression, and chromatin regulation in lung cancer remain poorly understood. Here, we demonstrate that loss of Smarca4 sensitizes club cell secretory protein–positive cells within the lung in a cell type–dependent fashion to malignant transformation and tumor progression, resulting in highly advanced dedifferentiated tumors and increased metastatic incidence. Consistent with these phenotypes, Smarca4-deficient primary tumors lack lung lineage transcription factor activities and resemble a metastatic cell state. Mechanistically, we show that Smarca4 loss impairs the function of all three classes of SWI/SNF complexes, resulting in decreased chromatin accessibility at lung lineage motifs and ultimately accelerating tumor progression. Thus, we propose that the SWI/SNF complex via Smarca4 acts as a gatekeeper for lineage-specific cellular transformation and metastasis during lung cancer evolution. SIGNIFICANCE: We demonstrate cell-type specificity in the tumor-suppressive functions of SMARCA4 in the lung, pointing toward a critical role of the cell-of-origin in driving SWI/SNF-mutant lung adenocarcinoma. We further show the direct effects of SMARCA4 loss on SWI/SNF function and chromatin regulation that cause aggressive malignancy during lung cancer evolution.
UR - http://www.scopus.com/inward/record.url?scp=85124444783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124444783&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-21-0248
DO - 10.1158/2159-8290.CD-21-0248
M3 - Article
C2 - 34561242
AN - SCOPUS:85124444783
SN - 2159-8274
VL - 12
SP - 562
EP - 585
JO - Cancer Discovery
JF - Cancer Discovery
IS - 2
ER -